Squarepoint Ops LLC lowered its stake in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 77.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,219 shares of the company's stock after selling 121,344 shares during the period. Squarepoint Ops LLC's holdings in Envista were worth $699,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the company. KBC Group NV grew its stake in Envista by 63.9% in the 4th quarter. KBC Group NV now owns 7,903 shares of the company's stock valued at $152,000 after buying an additional 3,082 shares in the last quarter. Lecap Asset Management Ltd. bought a new position in shares of Envista in the fourth quarter worth $281,000. Empowered Funds LLC purchased a new position in shares of Envista in the fourth quarter valued at $374,000. Lightrock Netherlands B.V. purchased a new position in shares of Envista in the fourth quarter valued at $5,193,000. Finally, Rhumbline Advisers raised its stake in shares of Envista by 1.4% during the 4th quarter. Rhumbline Advisers now owns 474,259 shares of the company's stock valued at $9,148,000 after purchasing an additional 6,421 shares during the period.
Analyst Upgrades and Downgrades
NVST has been the subject of several analyst reports. Morgan Stanley set a $16.00 target price on Envista in a research note on Tuesday, April 15th. Robert W. Baird raised shares of Envista from a "neutral" rating to an "outperform" rating and boosted their price objective for the company from $21.00 to $23.00 in a research note on Tuesday, May 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a report on Thursday, March 6th. New Street Research set a $19.00 price target on shares of Envista in a report on Thursday, March 6th. Finally, Wells Fargo & Company set a $19.00 price target on shares of Envista in a report on Saturday, March 8th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $20.23.
Get Our Latest Research Report on Envista
Envista Price Performance
NYSE:NVST traded up $0.09 during midday trading on Friday, hitting $18.77. The company had a trading volume of 1,271,354 shares, compared to its average volume of 2,567,430. The company has a market capitalization of $3.18 billion, a PE ratio of -2.89, a P/E/G ratio of 1.27 and a beta of 0.99. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. Envista Holdings Co. has a 52-week low of $14.22 and a 52-week high of $23.00. The stock's fifty day moving average price is $16.78 and its 200-day moving average price is $18.69.
Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.04. The firm had revenue of $616.90 million during the quarter, compared to analyst estimates of $608.17 million. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. The company's revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 earnings per share. As a group, research analysts expect that Envista Holdings Co. will post 1 earnings per share for the current year.
About Envista
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
